Inclusion Criteria

Inclusion criteria:

- Patients with CRPC progressing during the course of first line docetaxel-based
chemotherapy or after at least 3 cycles (equivalent to 225mg/m2) of first line
docetaxel-based chemotherapy

- Patient who have given their written consent

Exclusion criteria:

- Current participation in a clinical trial for the second-line treatment of prostate
cancer

- Patients having received less than 3 cycles of first line docetaxel-based
chemotherapy and discontinued for a reason other than disease progression or toxicity

- Patients having already started a second line treatment

The above information is not intended to contain all considerations relevant to a
patient's potential participation in a clinical trial.